Cardiovascular Data Articles & Analysis: Older
8 news found
New post-hoc analyses from the prespecified pooled analysis FIDELITY will provide insights into the effects of finerenone on kidney and cardiovascular outcomes by use of glucagon-like peptide-1 receptor agonists (GLP-1RA) at baseline, as well as by baseline HbA1c, HbA1c variability, and diabetes duration in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) ...
ByBayer AG
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today new data confirming excellent one-year outcomes with coronary IVL in both women and men. The one-year results from the Disrupt CAD clinical program were presented at the 2022 Scientific Sessions of the Society for ...
The presentation, entitledEffect of Icosapent Ethyl (IPE) on Changes in Coronary Plaque Morphology, details the effects of IPE on cardiovascular events and plaque characteristics using the ElucidVivo software on CT angiography (CTA). The ElucidVivo software is the first and only FDA-cleared arterial analysis tool designed to quantify morphology from CTA as if performed ex vivo by ...
ByElucid
The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) and cardiovascular disease and / or significant cardiovascular risk factors. This patient population is of particular relevance as cardiovascular disease is the most common and significant comorbidity of COPD, with approximately ...
The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) and cardiovascular disease and / or significant cardiovascular risk factors. This patient population is of particular relevance as cardiovascular disease is the most common and significant comorbidity of COPD, with approximately ...
Their analysis of studies in the PubMed and EMBASE databases from 1950 to 2018 provided nine eligible studies (all published in the past six years) providing data from 5,390,591 women and 101,424 cardiovascular events. Compared with those who did not have GDM, women with GDM had a doubled risk of future cardiovascular events. Further analysis of ...
The FDA has also accepted for review the Tudorza® supplemental NDA (sNDA) requesting the inclusion of new clinical data demonstrating cardiovascular safety and the reduction of COPD exacerbations in the product’s prescribing information. ...
Duaklir® NDA for treatment of chronic obstructive pulmonary disease (COPD) Tudorza® sNDA for inclusion of COPD exacerbation reduction and cardiovascular safety data in label Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today ...